Abnormal patterns of immunoglobulin heavy chain gene DNA fingerprinting during chronic phase chronic myeloid leukemia

A Spencer1, R Szydlo, F H Grand

  • 1Haematology Department, Mater Hospital, Newcastle, Australia. andrewspencer@hunterlink.net.au

Leukemia & Lymphoma
|February 26, 1999
PubMed

Insights

Abnormal immunoglobulin heavy chain (IgH) DNA fingerprints are common in chronic myeloid leukemia (CML) and may predict blast crisis. Interferon-alpha (IFN) therapy was associated with normal IgH fingerprints in CML patients.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Clonal immunoglobulin heavy chain (IgH) gene rearrangements are observed in chronic phase (CP) chronic myeloid leukemia (CML) patients who progress to lymphoid blast crisis (L-BC).
  • Understanding the frequency and implications of these rearrangements is crucial for predicting disease progression.

Purpose of the Study:

  • To determine the frequency of abnormal IgH DNA fingerprints in CP CML patients.
  • To investigate the relationship between IgH fingerprint patterns and treatment regimens, particularly interferon-alpha (IFN).
  • To assess the predictive value of IgH fingerprints for impending blast crisis in CML.

Main Methods:

  • A cohort of 33 CP CML patients was monitored over 16 months.
  • IgH DNA fingerprinting, using PCR amplification of the IgH gene's third complementarity determining region (CDR3) and polyacrylamide gel electrophoresis, was performed on 111 occasions.
  • Patients received either IFN-containing or non-IFN-containing regimens, or variable therapy.

Main Results:

  • Abnormal IgH fingerprints were detected in 26% (29/111) of analyzed specimens.
  • Patients receiving IFN-containing regimens consistently showed normal IgH fingerprints, while 10 of 15 patients on non-IFN regimens exhibited abnormalities (p = 0.00023).
  • Abnormal fingerprints correlated with elevated peripheral blood lymphocyte counts (p = 0.0001) and preceded the diagnosis of L-BC by 7 months in one patient.

Conclusions:

  • Abnormal IgH fingerprints are prevalent in CP CML patients.
  • Interferon-alpha (IFN) therapy is associated with the maintenance of normal IgH DNA fingerprints in CML.
  • Detection of abnormal IgH fingerprints may serve as a valuable predictor for the lineage of impending blast crisis in CML.